News Quantified

TCON – tracon pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.

TRACON Pharmaceuticals Announces Reverse Stock Split

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.

5.1%

BEAT

43.9%

MISS

-7.0%

BEAT

Form 8-K Tracon Pharmaceuticals, For: May 08

Form S-1 Tracon Pharmaceuticals,

Form 8-K Tracon Pharmaceuticals, For: Apr 12

Form 424B5 Tracon Pharmaceuticals,

Form 8-K Tracon Pharmaceuticals, For: Apr 08

Top News Gainers

3/10 TRACON Pharmaceuticals Inc (NASDAQ: TCON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, down previously from $13.00. 40.2%

4/14 TRACON Pharmaceuticals Announces Appointment of Biotechnology Industry Veteran Shahe Garabedian as Senior Vice President of Quality Assurance and Granting of Inducement Award 21.1%

2/28 TRACON Pharmaceuticals Inc (NASDAQ: TCON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock, down previously from $18.00. 13.0%

4/14 Form PRE 14A Tracon Pharmaceuticals, For: Jun 10 12.4%

3/16 TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma 12.0%

8/12 Form 4 Tracon Pharmaceuticals, For: Aug 09 Filed by: THEUER CHARLES 8.6%

2/7 TRACON Pharmaceuticals Announces Change to Nasdaq Capital Market 6.5%

10/17 Form 8-K Tracon Pharmaceuticals, For: Oct 16 4.5%

4/6 TRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma 4.4%

11/25 Form EFFECT Tracon Pharmaceuticals, 4.3%

Top News Decliners

3/9 Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration -19.1%

3/10 Form 4 Tracon Pharmaceuticals, For: Mar 10 Filed by: THEUER CHARLES -17.5%

4/24 TRACON Pharmaceuticals Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial -16.6%

10/21 Form 8-K Tracon Pharmaceuticals, For: Oct 18 -14.4%

2/28 Form 10-K Tracon Pharmaceuticals, For: Dec 31 -14.4%

1/13 Form 424B5 Tracon Pharmaceuticals, -14.3%

7/2 TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer -11.1%

8/1 I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors -10.0%

3/13 Form 4 Tracon Pharmaceuticals, For: Mar 13 Filed by: THEUER CHARLES -9.7%

8/29 TRACON Pharmaceuticals to Present at the 2019 Wells Fargo Securities Healthcare Conference -9.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day